XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Net product revenue$6,119.2 $6,189.0 $19,123.0 $18,579.5 
Collaboration and other revenue(1)
822.4 583.8 2,116.6 1,739.0 
Revenue$6,941.6 $6,772.8 $21,239.6 $20,318.5 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $43.3 million and $130.9 million during the three and nine months ended September 30, 2022, respectively, and $62.1 million and $136.1 million during the three and nine months ended September 30, 2021, respectively.
The following table summarizes revenue by product for the three months ended September 30, 2022 and 2021:
Three Months Ended September 30,
 20222021
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$1,418.3 $432.0 $1,850.4 $1,201.4 $398.8 $1,600.1 
Jardiance(1)
350.9 222.4 573.3 221.2 169.2 390.4 
Humalog® (2)
248.1 198.8 447.0 347.3 279.4 626.7 
Humulin®
169.5 68.7 238.2 193.4 93.4 286.7 
Basaglar®
124.8 68.1 193.0 114.7 78.1 192.8 
Mounjaro®
97.3 90.0 187.3 — — — 
Other diabetes79.7 94.0 173.4 65.0 112.2 177.4 
Total diabetes2,488.6 1,174.0 3,662.6 2,143.0 1,131.1 3,274.1 
Oncology:
Verzenio®
414.8 202.9 617.7 199.6 135.9 335.5 
Cyramza®
87.5 144.6 232.1 84.8 168.6 253.4 
Erbitux®
126.3 18.7 144.9 114.0 20.3 134.3 
Alimta®
64.6 54.8 119.4 297.2 159.8 457.0 
Tyvyt®
— 76.8 76.8 — 125.6 125.6 
Other oncology39.5 62.8 102.4 35.3 65.1 100.3 
Total oncology732.7 560.6 1,293.3 730.9 675.3 1,406.1 
Immunology:
Taltz®
493.8 186.1 679.9 422.2 170.9 593.1 
Olumiant® (3)
22.9 160.0 182.9 194.0 212.9 406.9 
Other immunology— 3.6 3.6 — 4.9 4.9 
Total immunology516.7 349.7 866.4 616.2 388.7 1,004.9 
Neuroscience:
Emgality®
114.0 54.6 168.5 99.9 40.1 140.0 
Zyprexa®
8.0 73.4 81.4 13.0 88.7 101.7 
Cymbalta®
7.8 54.9 62.7 7.0 125.1 132.0 
Other neuroscience16.0 44.5 60.6 24.7 51.6 76.5 
Total neuroscience145.8 227.4 373.2 144.6 305.5 450.2 
Other:
COVID-19 antibodies(4)
386.6 — 386.6 215.5 1.6 217.1 
Forteo®
112.7 64.4 177.1 109.6 91.3 200.9 
Cialis®
8.1 107.7 115.7 (6.5)137.4 130.9 
Other30.9 35.7 66.6 36.3 52.4 88.8 
Total other538.3 207.8 746.0 354.9 282.7 637.7 
Revenue$4,422.1 $2,519.4 $6,941.6 $3,989.6 $2,783.3 $6,772.8 
Numbers may not add due to rounding.
(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(2) Humalog revenue includes insulin lispro.
(3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by product for the nine months ended September 30, 2022 and 2021:
Nine Months Ended September 30,
 20222021
U.S.Outside U.S.TotalU.S.Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity$4,162.4 $1,341.1 $5,503.5 $3,465.7 $1,122.5 $4,588.2 
Humalog(1)
855.8 656.4 1,512.3 1,009.0 842.3 1,851.3 
Jardiance(2)
831.4 622.4 1,453.7 566.8 492.1 1,058.9 
Humulin562.3 223.1 785.4 633.5 290.3 923.8 
Basaglar339.9 218.8 558.7 423.3 226.8 650.1 
Mounjaro109.9 93.3 203.2 — — — 
Other diabetes195.6 276.5 472.2 185.7 302.6 488.3 
Total diabetes7,057.3 3,431.6 10,489.0 6,284.0 3,276.6 9,560.6 
Oncology:
Verzenio1,100.5 575.1 1,675.6 582.1 363.7 945.8 
Cyramza259.3 434.3 693.6 266.3 496.3 762.5 
Alimta490.5 200.5 691.1 911.9 714.7 1,626.6 
Erbitux361.0 47.4 408.3 357.7 45.9 403.7 
Tyvyt— 235.8 235.8 — 340.2 340.2 
Other oncology124.1 186.5 310.6 83.7 169.9 253.6 
Total oncology2,335.4 1,679.6 4,015.0 2,201.7 2,130.7 4,332.4 
Immunology:
Taltz1,212.6 561.6 1,774.2 1,071.6 493.8 1,565.4 
Olumiant(3)
104.6 520.1 624.7 236.5 572.6 809.1 
Other immunology0.1 12.1 12.1 15.2 14.5 29.7 
Total immunology1,317.3 1,093.8 2,411.0 1,323.3 1,080.9 2,404.2 
Neuroscience:
Emgality330.8 144.4 475.2 313.5 102.2 415.7 
Zyprexa26.2 235.5 261.7 28.3 264.5 292.8 
Cymbalta25.0 194.3 219.3 30.3 454.0 484.3 
Other neuroscience62.0 142.7 204.7 81.0 154.0 235.0 
Total neuroscience444.0 716.9 1,160.9 453.1 974.7 1,427.8 
Other:
COVID-19 antibodies(4)
1,970.9 14.7 1,985.5 949.5 226.7 1,176.2 
Cialis25.8 454.7 480.4 (3.1)541.8 538.7 
Forteo261.4 191.7 453.0 330.1 287.7 617.8 
Other119.4 125.1 244.8 96.5 164.3 260.8 
Total other2,377.5 786.2 3,163.7 1,373.0 1,220.5 2,593.5 
Revenue$13,531.5 $7,708.1 $21,239.6 $11,635.1 $8,683.4 $20,318.5 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(3) Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue—to unaffiliated customers(1):
U.S.$4,422.1 $3,989.6 $13,531.5 $11,635.1 
Europe1,056.4 1,098.6 3,224.8 3,629.6 
Japan487.7 595.0 1,352.3 1,832.2 
China343.4 400.3 1,102.0 1,285.0 
Other foreign countries632.0 689.4 2,029.1 1,936.7 
Revenue$6,941.6 $6,772.8 $21,239.6 $20,318.5 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Schedule of amounts recorded for contract liabilities
The following table summarizes contract liability balances:
 September 30, 2022December 31, 2021
Contract liabilities$232.5 $262.6